San Francisco Business Times: Stanford serial entrepreneurs Stephen Quake and Michael Clarke are at it again — now with a potentially broad cancer blocker
Archives: News
This is the news post type
Aug 24, 2022
Tachyon Receives IND Clearance from FDA to Develop Novel KDM4 Inhibitor TACH101 for Advanced Solid Tumors
Apr 8, 2022
Tachyon Presents TACH101 Preclinical Data at the 2022 AACR Conference
Jan 20, 2022
Tachyon Presents TACH101 Data at the 2022 ASCO-GI Conference
Oct 8, 2021
Tachyon Presents TACH101 Data at the 2021 AACR-NCI-EORTC Conference
Sep 17, 2021
Tachyon Announces Presentation at the 2021 ESMO Annual Meeting
Aug 3, 2021
Tachyon Announces Collaboration with AbCellera to Develop Novel Therapeutic Against LEFTY1 for Advanced Cancer
Jun 4, 2021
Tachyon Announces Presentations at the ASCO Annual Meeting
Apr 10, 2021
Tachyon Presents Promising Preclinical Data on its First-in-Class pan-KDM4 Epigenetic Regulator, TACH101, at the AACR Annual Meeting
Apr 10, 2020
Tachyon Presents Promising Preclinical Data on its First-in-Class pan-KDM4 Epigenetic Regulator, TACH101, at the AACR Annual Meeting
Recent Comments